Literature DB >> 27649320

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Yi Su, Tyler M Blazey, Christopher J Owen, Jon J Christensen, Karl Friedrichsen, Nelly Joseph-Mathurin, Qing Wang, Russ C Hornbeck, Beau M Ances, Abraham Z Snyder, Lisa A Cash, Robert A Koeppe, William E Klunk, Douglas Galasko, Adam M Brickman, Eric McDade, John M Ringman, Paul M Thompson, Andrew J Saykin, Bernardino Ghetti, Reisa A Sperling, Keith A Johnson, Stephen P Salloway, Peter R Schofield, Colin L Masters, Victor L Villemagne, Nick C Fox, Stefan Förster, Kewei Chen, Eric M Reiman, Chengjie Xiong, Daniel S Marcus, Michael W Weiner, John C Morris, Randall J Bateman, Tammie L S Benzinger.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0152082.].

Entities:  

Year:  2016        PMID: 27649320      PMCID: PMC5029931          DOI: 10.1371/journal.pone.0163669

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


There are errors in the published article. Incorrect sample sizes were reported in Table 4 and Table 6. The intended sample size calculation was based on two-sided two-sample t-test to estimate the number of participants per arm needed to detect the specified reduction in amyloid accumulation rate due to treatment with 80% power and two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial. The tables with corrected sample size values can be seen here. MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference; MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference; MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction; delta = change in SUVR from baseline to follow-up; delta% = percent change in SUVR from baseline to follow-up; p is the strength of the difference between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR change; sample size is the estimated number of participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to treatment with 80% power and a two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial. *percent change in MCSUVR significantly greater with PVC than without (p<0.0005) †percent change in MCSUVR significantly smaller than CW referencing (p<0.01) ‡percent change in MCSUVR with PVC significantly smaller than CW referencing (p<0.05) MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference; MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference; MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction; MCBP = mean cortical binding potential; MCBPRSF = mean cortical binding potential with RSF partial volume correction; delta = change in SUVR from baseline to follow-up; p is the strength of the difference between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR change; sample size is the estimated number of participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to treatment with 80% power and a two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.
Table 4

Longitudinal SUVR analysis for mean cortical regions in mutation carriers.

 MC_CERMC_BSMC_CWMC_TWMCRSF_CERMCRSF_BSMCRSF_CWMCRSF_TW
Baseline1.73±0.581.15±0.351.08±0.310.99±0.142.54±1.281.43±0.631.53±0.731.43±0.56
follow-up1.76±0.601.17±0.351.12±0.321.00±0.142.65±1.361.48±0.641.64±0.801.49±0.57
delta0.03±0.110.01±0.070.04±0.070.01±0.030.11±0.260.05±0.100.11±0.170.06±0.11
delta%1.63±7.041.51±6.303.34±5.881.29±3.544.19±11.07*4.08±9.86*7.03±11.27*5.05±9.82*
p (follow-up vs. Baseline)7.22E-021.39E-011.70E-058.12E-038.78E-046.25E-047.46E-061.14E-04
Rate0.01±0.080.00±0.040.02±0.040.01±0.020.07±0.180.02±0.060.07±0.130.04±0.07
Effect Size0.150.070.550.380.380.380.510.50
sample size (25% reduction in Rate)11425480168191744171217019561001
sample size (50% reduction in rate)285712005206437429426240251

MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference; MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference; MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction; delta = change in SUVR from baseline to follow-up; delta% = percent change in SUVR from baseline to follow-up; p is the strength of the difference between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR change; sample size is the estimated number of participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to treatment with 80% power and a two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.

*percent change in MCSUVR significantly greater with PVC than without (p<0.0005)

†percent change in MCSUVR significantly smaller than CW referencing (p<0.01)

‡percent change in MCSUVR with PVC significantly smaller than CW referencing (p<0.05)

Table 6

Mean cortical measurement for longitudinal cohort participants with full dynamic PiB.

 MC_CERMC_BSMC_CWMC_TWMCRSF_CERMCRRSF_BSMCRRSF_CWMCRRSF_TWMCBPMCBPRSF
Baseline1.83±0.591.18±0.351.12±0.311.02±0.162.80±1.331.50±0.641.60±0.711.54±0.620.62±0.451.33±0.93
follow-up1.89±0.581.22±0.351.16±0.321.03±0.152.93±1.331.58±0.661.71±0.751.60±0.620.67±0.451.43±0.95
delta0.05±0.130.04±0.060.04±0.050.01±0.040.14±0.290.09±0.090.11±0.120.06±0.110.05±0.100.10±0.22
p (follow-up vs. Baseline)6.34E-021.98E-034.47E-048.39E-023.33E-022.02E-041.68E-041.19E-022.91E-023.84E-02
Rate0.02±0.090.02±0.030.02±0.030.00±0.020.05±0.170.04±0.050.05±0.060.03±0.050.02±0.050.04±0.11
Effect Size0.230.620.710.250.330.850.820.490.330.34
sample size (25% reduction in Rate)457066249940722339350373103423502192
sample size (50% reduction in rate)114316712610195868994260589549

MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference; MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference; MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction; MCBP = mean cortical binding potential; MCBPRSF = mean cortical binding potential with RSF partial volume correction; delta = change in SUVR from baseline to follow-up; p is the strength of the difference between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR change; sample size is the estimated number of participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to treatment with 80% power and a two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.

  1 in total

1.  Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Authors:  Yi Su; Tyler M Blazey; Christopher J Owen; Jon J Christensen; Karl Friedrichsen; Nelly Joseph-Mathurin; Qing Wang; Russ C Hornbeck; Beau M Ances; Abraham Z Snyder; Lisa A Cash; Robert A Koeppe; William E Klunk; Douglas Galasko; Adam M Brickman; Eric McDade; John M Ringman; Paul M Thompson; Andrew J Saykin; Bernardino Ghetti; Reisa A Sperling; Keith A Johnson; Stephen P Salloway; Peter R Schofield; Colin L Masters; Victor L Villemagne; Nick C Fox; Stefan Förster; Kewei Chen; Eric M Reiman; Chengjie Xiong; Daniel S Marcus; Michael W Weiner; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

  1 in total
  1 in total

Review 1.  Alzheimer's disease and blood-based biomarkers - potential contexts of use.

Authors:  Martina Zvěřová
Journal:  Neuropsychiatr Dis Treat       Date:  2018-07-20       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.